Business
Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office
Registration link below for Wednesday March 18, 2026 at 4 PM EDT Phio invites individual and institutional investors, as well as advisors and analysts with an
About this update from Phio Pharmaceuticals Corp.
[{"type":"text","content":"Registration link below for Wednesday March 18, 2026 at 4 PM EDT\nPhio invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend this virtual event\nKing of Prussia, Pennsylvania--(Newsfile Corp. - March 16, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Steven Saltzstein, CEO, Force Family Office on Wednesday March 18, 2026.\n\"We are excited to participate in the fireside chat with Force Family Office and look forward to sharing the Phio story and why we believe INTASYL represents a differentiated approach to immuno-oncology,\" said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals.\nDATE: Wednesday March 18, 2026\nTIME: 4 PM EDT\nREGISTRATION LINK: PHIO Pharma - Force Family Office\nRecent Company HighlightsPhio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma. In its Phase 1b trial, Phio has reported that 22 patients completed treatment across five dose-escalation cohorts, with no dose-limiting toxicities or serious adverse events. The Company has also reported a pathological response rate in cSCC across all dosing cohorts of approximately 65%, including an 85% pathological response (6 of 7 patients) in the highest-dose cohort.\nPhio has indicated that FDA engagement regarding next-stage clinical development is targeted for the second quarter of 2026 and has reported cash and cash equivalents projected to sustain operations into the first half of 2027.\nAbout Phio Pharmaceuticals Corp.Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL® gene silencing technology focused on immuno-oncology therapeutics. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 060140...